

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the prospectus dated July 31, 2025 (the “**Prospectus**”) issued by Ab&B Bio-Tech CO., LTD. JS (江蘇中慧元通生物科技股份有限公司) (the “**Company**”) for detailed information about the Global Offering described below before deciding whether or not to invest in the H Shares thereby being offered. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information in the Prospectus.*

Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.



Ab&B Bio-Tech

Ab&B Bio-Tech CO., LTD. JS

江蘇中慧元通生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

POSTPONEMENT OF EXPECTED TIMETABLE OF THE GLOBAL OFFERING DUE TO BAD WEATHER

Reference is made to the Prospectus and the formal notice of the Company dated 31 July 2025 (the “**Formal Notice**”). Unless otherwise stated, terms used in this announcement shall have the same meanings as defined in the Prospectus and the Formal Notice.

Due to the black rainstorm warning and extreme conditions caused by the bad weather in the morning on 5 August 2025, the expected timetable of the Global Offering as set out in the Prospectus and the Formal Notice will be accordingly postponed. The Company hereby announces that an updated expected timetable will be adopted for the Global Offering, details of which are set out as follows.

EXPECTED TIMETABLE

Date⁽¹⁾

Hong Kong Public Offering commences..... 9:00 a.m. on
Thursday, July 31, 2025

Latest time for completing electronic applications under
the **HK eIPO White Form** service through
the designated website at www.hkeipo.hk..... 11:30 a.m. on
Wednesday, August 6,
2025

Application lists open..... 11:45 a.m. on
Wednesday, August 6,
2025

Latest time for (a) completing payment of **HK eIPO White Form**
applications by effecting internet banking transfer(s)
or PPS payment transfer(s) and (b) giving
electronic application instructions to HKSCC..... 12:00 noon on
Wednesday, August 6,
2025

If you are instructing your broker or custodian who is a HKSCC Participant will submit an EIPO application on your behalf through HKSCC's FINI system in accordance with your instruction, you are advised to contact your broker or custodian for the earliest and latest time for giving such instructions, as this may vary by broker or custodian.

Application lists close..... 12:00 noon on
Wednesday, August 6,
2025

Expected Price Determination Date..... on or before 12:00 noon,
Thursday, August 7, 2025

Announcement of the Offer Price, the level of indications
of interest in the International Offering, the level of
applications in the Hong Kong Public Offering and
the basis of allocation of the Hong Kong Offer Shares
to be published on the website of the Stock Exchange
at www.hkexnews.hk and on the Company's website
at <http://www.abbbio.com> at or before 11:00 p.m. on
Friday, August 8, 2025

The results of allocations in the Hong Kong Public Offering (with successful applicants' identification document numbers, where appropriate) to be available through a variety of channels, including:

- in the announcement to be posted on our website and the website of the Stock Exchange at <http://www.abbbio.com> and www.hkexnews.hk, respectively..... at or before 11:00 p.m. on Friday, August 8, 2025
- Results of allocation for the Hong Kong Public Offering will be available at the “Allotment Results” page from the designated results of allocations website at www.hkeipo.hk/IPOResult (or www.tricor.com.hk/ipo/result) with a “search by ID” function from 11:00 p.m. on Friday, August 8, 2025 to 12:00 midnight on Thursday, August 14, 2025
- from the allocation results telephone enquiry line by calling +852 3691 8488 between 9:00 a.m. and 6:00 p.m. from Monday, August 11, 2025 to Thursday, August 14, 2025 (except Saturday, Sunday and public holidays in Hong Kong)

H Share certificates in respect of wholly or partially successful applications to be dispatched or deposited into CCASS on or before.....Friday, August 8, 2025

HK eIPO White Form e-Auto Refund payment instructions/refund checks in respect of (i) wholly or partially successful applications if the final Offer Price is less than the price payable on application (if applicable) and (ii) wholly or partially unsuccessful application under the Hong Kong Public Offering to be dispatched on or before..... Monday, August 11, 2025

Dealings in the Shares on the Stock Exchange expected to commence at..... 9:00 a.m. on Monday, August 11, 2025

Notes:

- 1 All times and dates refer to Hong Kong local times and dates unless otherwise stated.

ELECTRONIC APPLICATION CHANNELS

To apply for Hong Kong Offer Shares, you may use one of the following application channels:

Application Channel	Platform	Target Investors	Application Time
HK eIPO White Form service	<u>www.hkeipo.hk</u>	Investors who would like to receive a physical H Share certificate. Hong Kong Offer Shares successfully applied for will be allotted and issued in your own name.	From 9:00 a.m. on Thursday, July 31, 2025 to 11:30 a.m. on Wednesday, August 6, 2025, Hong Kong time. The latest time for completing full payment of application monies will be 12:00 noon on Wednesday, August 6, 2025, Hong Kong time.
HKSCC EIPO channel	Your broker or custodian who is a HKSCC Participant will submit electronic application instruction(s) on your behalf through HKSCC's FINI system in accordance with your instruction.	Investors who would not like to receive a physical H Share certificate. Hong Kong Offer Shares successfully applied for will be allotted and issued in the name of HKSCC Nominees, deposited directly into CCASS and credited to your designated HKSCC Participant's stock account.	Contact your broker or custodian for the earliest and latest time for giving such instructions, as this may vary by broker or custodian .

For those applying through the **HK eIPO White Form** service, the application monies (including brokerage, SFC transaction levy, AFRC transaction levy and Stock Exchange trading fee) will be held by the **HK eIPO White Form** Service Provider on behalf of the Company and the refund monies, if any, will be returned to you without interest on Monday, August 11, 2025. Investors should be aware that the dealings in the H Shares on the Stock Exchange are expected to commence on Monday, August 11, 2025.

Please refer to the sections headed “Structure of the Global Offering” and “How to Apply for Hong Kong Offer Shares” in the Prospectus for details of the conditions and procedures of the Hong Kong Public Offering.

Application for the Hong Kong Offer Shares will only be considered on the basis of the terms and conditions set out in the Prospectus and on the designated website at www.hkeipo.hk for the HK eIPO White Form service.

PUBLICATION OF RESULTS

The Company expects to announce the final Offer Price, the level of indications of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares on the Stock Exchange’s website at www.hkexnews.hk and our website at www.abbbio.com by no later than 11:00 p.m. on Friday, August 8, 2025 (Hong Kong time).

The results of allocations and the identification document numbers of successful applicants under the Hong Kong Public Offering will be available through a variety of channels at the times and dates and in the manner specified in the section headed “How to Apply for Hong Kong Offer Shares – B. Publication of Results” in the Prospectus.

If an application is rejected, not accepted or accepted in part only, or if the conditions of the Global Offering as set out in the section headed “Structure of the Global Offering – Conditions of the Global Offering” in the Prospectus are not satisfied or if any application is revoked, the application monies, or the appropriate portion thereof, together with the related brokerage, SFC transaction levy, AFRC transaction levy and Stock Exchange trading fee, will be refunded (subject to application channels), without interest.

No temporary document of title will be issued in respect of the H Shares. No receipt will be issued for sums paid on application. H Share certificates will only become valid evidence of title at 8:00 a.m. on Monday, August 11, 2025 (Hong Kong time), provided that the Global Offering has become unconditional and the right of termination described in the section headed “Underwriting” in the Prospectus has not been exercised. Investors who trade H Shares prior to the receipt of H Share certificates or the H Share certificates becoming valid do so entirely at their own risk. Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. in Hong Kong on Monday, August 11, 2025, it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Monday, August 11, 2025. The H Shares will be traded in board lots of 200 H Shares each and the stock code of the H Shares will be 2627.

This announcement is available for viewing on the website of the Company at www.abbbio.com and the website of the Stock Exchange at www.hkexnews.hk.

By order of the Board
Ab&B Bio-Tech CO., LTD. JS
Mr. AN Youcai

Executive Director, chairman of the Board and general manager

Hong Kong, August 5, 2025

As at the date of this announcement, the Board comprises: (i) Mr. AN Youcai, Ms. LI Runxiang and Mr. HE Yiming as executive Directors; (ii) Mr. CHENG Qianwen, Mr. YU Jianlin and Mr. DU Mu as non-executive Directors; and (iii) Mr. LI Xiangming, Ms. LI Xiaoqing and Mr. CHEN Chengbei as independent non-executive Directors.